2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. Sirtuin
  5. SIRT7 Isoform

SIRT7

SIRT7 is a mammalian sirtuin and NAD+-dependent histone/protein deacetylase involved in genome stability, metabolism, stress responses, tumorigenesis, ribosome biogenesis, and transcriptional regulation[1]. Mechanistically, DNA activates SIRT7 to deacetylate histone H3 in chromatin, and RNA increases SIRT7 catalytic efficiency while ribosomal RNA acts as a predominant binding partner[1][2]. Therefore, SIRT7 connects nucleolar biology with chromatin regulation through deacetylation of fibrillarin, maintenance of H2AQ104 methylation, and support of cell-cycle-dependent rDNA transcription[3]. SIRT7 also deacetylates ribosomal RNA ac4C, indicating an epitranscriptional role in rRNA modification and aging-related regulation[4]. In DNA damage models, SIRT7 promotes genome integrity by PARP1-dependent recruitment to DNA damage sites, H3K18Ac modulation, 53BP1 recruitment, and non-homologous end joining repair[5]. In cellular senescence models, SIRT7 supports SNF2H association with rDNA sequences and protects against rDNA instability, rDNA copy loss, and acute senescence[6]. Compared with SIRT6, SIRT7 shows a distinct activation mechanism because DNA activates SIRT7 peptide deacetylation, whereas SIRT6 peptide deacetylation is not DNA-activated[1]. For experimental applications, improved DNA- or RNA-activated enzymatic assays and SIRT7 lysine deacylase profiling support development of SIRT7 modulators[1][2][7].

SIRT7 Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-135899
    SIRT7 inhibitor 97491
    		Inhibitor 98.81%
    SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway..
  • HY-159124
    YZL-51N
    		Inhibitor
    YZL-51N is a selective SIRT7 inhibitor with IC50 value of 12.71 μM. YZL-51N disrupts SIRT7 enzyme activity by occupying the NAD+ binding pocket, thereby weakening DNA damage repair and inhibiting cancer cell survival. YZL-51N possesses anti-tumor activity and can be used in cancer research.
  • HY-150727
    SIRT5 inhibitor 4
    		Inhibitor 98.37%
    SIRT5 inhibitor 4 (compound 11) is a potent, selective SIRT5 inhibitor with IC50 values of 26.4 and >400μM for SIRT5 and other SIRT subtype, respectively.
  • HY-156489
    Epigenetic factor-IN-1
    		Inhibitor
    Epigenetic factor-IN-1 (40569Z) is a epigenetic factor inhibitor. Epigenetic factor-IN-1 has strong binding effect on SIRT7. Epigenetic factor-IN-1 can be used for liver cancer research.